Qingbo Liu

机构：Shenyang Pharmaceutical University, Guilin Medical University · ORCID：0000-0002-1347-6636

发表论文 77 篇 · 总被引 1124 次 · h-index 18

代表论文

• A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques (2021 · Nature Medicine · 被引 168)
• A comprehensive review: Biological activity, modification and synthetic methodologies of prenylated flavonoids (2021 · Phytochemistry · 被引 102)
• Anti-PF4 antibodies associated with disease severity in COVID-19 (2022 · Proceedings of the National Academy of Sciences · 被引 29)
• P-selectin glycoprotein ligand-1 (PSGL-1/CD162) is incorporated into clinical HIV-1 isolates and can mediate virus capture and subsequent transfer to permissive cells (2022 · Retrovirology · 被引 19)
• Protective role of activating PPARγ in advanced glycation end products-induced impairment of coronary artery vasodilation via inhibiting p38 phosphorylation and reactive oxygen species production (2022 · Biomedicine & Pharmacotherapy · 被引 13)
• Anti‐hepatitis B virus activity and hepatoprotective effect of des(rhamnosyl) verbascoside from Lindernia ruellioides in vitro (2021 · Phytotherapy Research · 被引 11)